Episode
EMV Capital advances XF-73 toward late-stage trials for surgical infection prevention
- Published
- May 28, 2026
- Duration seconds
- 619
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/proactive-interviews-for-investors-1457173/episodes/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/proactive-interviews-for-investors-1457173/emv-capital-advances-xf-73-toward-late-stage-trials-for-surgical-infection-prevention.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
EMV Capital CEO Dr. Ilian Iliev and Executive Chairman Nigel Brooksby joined Steve Darling from Proactive to discuss the company’s progress in advancing XF-73, an antimicrobial drug candidate designed to help prevent surgical site infections. The program represents an important step in addressing a significant healthcare challenge, particularly as hospitals and healthcare systems continue searching for more effective approaches to reduce infection risks and improve patient outcomes. XF-73 is being developed as a first-in-class topical antimicrobial treatment intended to rapidly eliminate harmful bacteria before surgery. The therapy targets bacteria commonly found in the nasal cavity that can contribute to post-surgical infections and complications. Management highlighted that a previous Phase 2 clinical study demonstrated a 99.5% reduction in bacterial nasal carriage within just 24 hours among surgical patients, providing encouraging support for the treatment’s potential effectiveness. The company acquired XF-73 and related intellectual property from Destiny Pharma in September 2025 through its Morai Acquisitions vehicle, which was subsequently renamed AMR Bio. Following the transaction, EMV Capital completed a funding round of approximately £1.3 million aimed at supporting the establishment and continued development of the new business. Brooke explained that several important regulatory milestones are expected to drive progress for the program. Planned near-term activities include filing an Investigational New Drug application for XF-73 Nasal, preparing for a Phase 3 trial, qualifying Infectious Disease Product designation, and advancing discussions with the U.S. Food and Drug Administration. The company also announced that Cardinal Health has been appointed as AMR Bi…